Abbott issues urgent correction for FreeStyle Libre 3 Sensors amid safety concerns

Globally, Abbott has received reports of 736 severe adverse events linked to the issue, including seven deaths (none in the US)

Global healthcare leader Abbott has launched a US-wide correction for certain FreeStyle Libre 3 and Libre 3 Plus glucose sensors after internal testing revealed some may deliver inaccurate low glucose readings. 

The company warns that these false readings could lead people with diabetes to make dangerous treatment decisions—such as consuming too many carbohydrates or skipping insulin—which can result in serious health risks, including injury or death. 

Abbott traced the problem to a single production line and says it has resolved the issue. The company is continuing production and does not anticipate major supply disruptions. Approximately 3 million sensors in the U.S. are affected, though roughly half may have already been used or expired. 

Globally, Abbott has received reports of 736 severe adverse events linked to the issue, including seven deaths (none in the US). 

Consumers are urged to check their sensors at www.FreeStyleCheck.com. Any affected sensors will be replaced free of charge. Abbott advises anyone currently using a potentially affected sensor to stop using it immediately and rely on a blood glucose meter or the reader’s built-in meter to guide treatment decisions.